Nano-Enabled Postbiotics in Functional Foods: Stability Challenges, Gastrointestinal Fate, and Translational Perspectives.
Abstract
The increasing demand for preventive and personalized nutrition has driven rapid growth in functional food development. These foods are designed not only to provide basic nutrition but also to deliver health-promoting bioactive compounds at specific sites. Postbiotics comprise nonviable microbial cells, cell components, and microbial metabolites. They have emerged as promising alternatives to live probiotics because of their improved safety, stability, and well-defined biological functions. These components can support epithelial barrier integrity, metabolic regulation, and immune modulation. However, their application in functional foods remains limited by poor stability, gastrointestinal (GI) degradation, food-matrix interactions, and low bioavailability following oral administration. This review discusses the major physicochemical and biological barriers affecting postbiotic stability and functionality. These include thermal degradation, pH instability, enzymatic breakdown, food-matrix interactions, and storage-related losses. It also highlights nano-enabled delivery systems for improving postbiotic delivery. The main systems include liposomes, polymeric nanoparticles, nanogels, nanoemulsions, and solid lipid nanoparticles. Among these, nanoemulsions may offer comparatively greater translational promise for food applications because of their established processing, scalability, and compatibility with liquid and semisolid food matrices. Although the suitability of nanoemulsions depends on postbiotic properties and remains constrained by interfacial instability, oxidation, and food-matrix interactions. These systems can improve protection, controlled release, GI targeting, and epithelial uptake. However, regulatory uncertainty, scale-up challenges, economic constraints, and limited clinical evidence continue to hinder practical application. Future progress will depend on standardized characterization methods, long-term clinical validation, comprehensive safety assessment, scalable manufacturing, regulatory harmonization, and commercialization.
Abstract as supplied by the indexing source. © the authors / publisher.